nodes	percent_of_prediction	percent_of_DWPC	metapath
Salicylate-sodium—PTGS1—malignant glioma	0.585	0.636	CbGaD
Salicylate-sodium—PTGS2—malignant glioma	0.335	0.364	CbGaD
Salicylate-sodium—Clotting—Temozolomide—malignant glioma	0.00322	0.0604	CcSEcCtD
Salicylate-sodium—Burning sensation—Carmustine—malignant glioma	0.00171	0.0321	CcSEcCtD
Salicylate-sodium—Acetylsalicylic acid—TP53—malignant glioma	0.00157	0.212	CrCbGaD
Salicylate-sodium—Necrosis—Carmustine—malignant glioma	0.00152	0.0284	CcSEcCtD
Salicylate-sodium—Abscess—Carmustine—malignant glioma	0.00151	0.0282	CcSEcCtD
Salicylate-sodium—Coagulopathy—Temozolomide—malignant glioma	0.00148	0.0277	CcSEcCtD
Salicylate-sodium—Extravasation—Carmustine—malignant glioma	0.00136	0.0256	CcSEcCtD
Salicylate-sodium—Hearing impaired—Temozolomide—malignant glioma	0.00121	0.0227	CcSEcCtD
Salicylate-sodium—Skin exfoliation—Carmustine—malignant glioma	0.00114	0.0213	CcSEcCtD
Salicylate-sodium—Skin exfoliation—Temozolomide—malignant glioma	0.0011	0.0206	CcSEcCtD
Salicylate-sodium—Sepsis—Carmustine—malignant glioma	0.00103	0.0194	CcSEcCtD
Salicylate-sodium—Phlebitis—Carmustine—malignant glioma	0.001	0.0188	CcSEcCtD
Salicylate-sodium—Swelling—Carmustine—malignant glioma	0.00098	0.0184	CcSEcCtD
Salicylate-sodium—Deafness—Temozolomide—malignant glioma	0.000934	0.0175	CcSEcCtD
Salicylate-sodium—Magnesium salicylate—PTGS1—malignant glioma	0.000847	0.114	CrCbGaD
Salicylate-sodium—Mesalazine—PPARG—malignant glioma	0.000846	0.114	CrCbGaD
Salicylate-sodium—Hypokalaemia—Carmustine—malignant glioma	0.000787	0.0147	CcSEcCtD
Salicylate-sodium—Dehydration—Temozolomide—malignant glioma	0.000777	0.0146	CcSEcCtD
Salicylate-sodium—Hypokalaemia—Temozolomide—malignant glioma	0.00076	0.0142	CcSEcCtD
Salicylate-sodium—Dysphagia—Carmustine—malignant glioma	0.000747	0.014	CcSEcCtD
Salicylate-sodium—PTGS2—S1P1 pathway—SPHK1—malignant glioma	0.000743	0.0375	CbGpPWpGaD
Salicylate-sodium—Abdominal distension—Temozolomide—malignant glioma	0.000727	0.0136	CcSEcCtD
Salicylate-sodium—Dysphagia—Temozolomide—malignant glioma	0.000722	0.0135	CcSEcCtD
Salicylate-sodium—Salsalate—PTGS1—malignant glioma	0.00072	0.0973	CrCbGaD
Salicylate-sodium—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS1—malignant glioma	0.000704	0.0355	CbGpPWpGaD
Salicylate-sodium—Sweating increased—Temozolomide—malignant glioma	0.000703	0.0132	CcSEcCtD
Salicylate-sodium—Bronchitis—Temozolomide—malignant glioma	0.000694	0.013	CcSEcCtD
Salicylate-sodium—Weight increased—Temozolomide—malignant glioma	0.000657	0.0123	CcSEcCtD
Salicylate-sodium—Renal failure—Carmustine—malignant glioma	0.000655	0.0123	CcSEcCtD
Salicylate-sodium—Mesalazine—PTGS1—malignant glioma	0.000625	0.0844	CrCbGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—YEATS4—malignant glioma	0.000624	0.0315	CbGpPWpGaD
Salicylate-sodium—Hypoaesthesia—Carmustine—malignant glioma	0.000595	0.0111	CcSEcCtD
Salicylate-sodium—Hallucination—Carmustine—malignant glioma	0.000595	0.0111	CcSEcCtD
Salicylate-sodium—Hepatitis—Temozolomide—malignant glioma	0.000578	0.0108	CcSEcCtD
Salicylate-sodium—Hypoaesthesia—Temozolomide—malignant glioma	0.000575	0.0108	CcSEcCtD
Salicylate-sodium—Hallucination—Temozolomide—malignant glioma	0.000575	0.0108	CcSEcCtD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—PTGS1—malignant glioma	0.000552	0.0278	CbGpPWpGaD
Salicylate-sodium—Erythema multiforme—Temozolomide—malignant glioma	0.000546	0.0102	CcSEcCtD
Salicylate-sodium—Tinnitus—Temozolomide—malignant glioma	0.000539	0.0101	CcSEcCtD
Salicylate-sodium—Acetylsalicylic acid—PTGS1—malignant glioma	0.000538	0.0726	CrCbGaD
Salicylate-sodium—Arrhythmia—Carmustine—malignant glioma	0.000534	0.01	CcSEcCtD
Salicylate-sodium—Erythema—Carmustine—malignant glioma	0.000521	0.00975	CcSEcCtD
Salicylate-sodium—Erythema—Temozolomide—malignant glioma	0.000503	0.00943	CcSEcCtD
Salicylate-sodium—Dysgeusia—Temozolomide—malignant glioma	0.000493	0.00923	CcSEcCtD
Salicylate-sodium—Vision blurred—Carmustine—malignant glioma	0.000491	0.00919	CcSEcCtD
Salicylate-sodium—Magnesium salicylate—PTGS2—malignant glioma	0.000484	0.0654	CrCbGaD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—PTK2—malignant glioma	0.000483	0.0244	CbGpPWpGaD
Salicylate-sodium—Vision blurred—Temozolomide—malignant glioma	0.000474	0.00888	CcSEcCtD
Salicylate-sodium—PTGS2—Eicosanoid Synthesis—PTGS1—malignant glioma	0.000458	0.0231	CbGpPWpGaD
Salicylate-sodium—Convulsion—Carmustine—malignant glioma	0.000451	0.00845	CcSEcCtD
Salicylate-sodium—Palpitations—Temozolomide—malignant glioma	0.000445	0.00833	CcSEcCtD
Salicylate-sodium—Chest pain—Carmustine—malignant glioma	0.000443	0.0083	CcSEcCtD
Salicylate-sodium—Salicylic acid—PTGS1—malignant glioma	0.000443	0.0598	CrCbGaD
Salicylate-sodium—Anxiety—Carmustine—malignant glioma	0.000442	0.00828	CcSEcCtD
Salicylate-sodium—Convulsion—Temozolomide—malignant glioma	0.000436	0.00817	CcSEcCtD
Salicylate-sodium—Confusional state—Carmustine—malignant glioma	0.000428	0.00803	CcSEcCtD
Salicylate-sodium—Anxiety—Temozolomide—malignant glioma	0.000427	0.008	CcSEcCtD
Salicylate-sodium—Oedema—Carmustine—malignant glioma	0.000425	0.00796	CcSEcCtD
Salicylate-sodium—PTGS2—Spinal Cord Injury—ROS1—malignant glioma	0.000424	0.0214	CbGpPWpGaD
Salicylate-sodium—Infection—Carmustine—malignant glioma	0.000422	0.00791	CcSEcCtD
Salicylate-sodium—Tachycardia—Carmustine—malignant glioma	0.000415	0.00777	CcSEcCtD
Salicylate-sodium—Confusional state—Temozolomide—malignant glioma	0.000414	0.00776	CcSEcCtD
Salicylate-sodium—Salsalate—PTGS2—malignant glioma	0.000412	0.0556	CrCbGaD
Salicylate-sodium—Anaphylactic shock—Temozolomide—malignant glioma	0.000411	0.00769	CcSEcCtD
Salicylate-sodium—Oedema—Temozolomide—malignant glioma	0.000411	0.00769	CcSEcCtD
Salicylate-sodium—Infection—Temozolomide—malignant glioma	0.000408	0.00764	CcSEcCtD
Salicylate-sodium—Anorexia—Carmustine—malignant glioma	0.000405	0.00759	CcSEcCtD
Salicylate-sodium—Hypotension—Carmustine—malignant glioma	0.000397	0.00744	CcSEcCtD
Salicylate-sodium—Hyperhidrosis—Temozolomide—malignant glioma	0.000397	0.00744	CcSEcCtD
Salicylate-sodium—Anorexia—Temozolomide—malignant glioma	0.000391	0.00733	CcSEcCtD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—PTK2—malignant glioma	0.000384	0.0194	CbGpPWpGaD
Salicylate-sodium—PTGS2—Prostaglandin Synthesis and Regulation—PTGS1—malignant glioma	0.000383	0.0193	CbGpPWpGaD
Salicylate-sodium—Paraesthesia—Carmustine—malignant glioma	0.000381	0.00715	CcSEcCtD
Salicylate-sodium—Dyspnoea—Carmustine—malignant glioma	0.000379	0.0071	CcSEcCtD
Salicylate-sodium—Somnolence—Carmustine—malignant glioma	0.000378	0.00708	CcSEcCtD
Salicylate-sodium—Decreased appetite—Carmustine—malignant glioma	0.000369	0.00692	CcSEcCtD
Salicylate-sodium—Paraesthesia—Temozolomide—malignant glioma	0.000369	0.00691	CcSEcCtD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—FN1—malignant glioma	0.000366	0.0185	CbGpPWpGaD
Salicylate-sodium—Dyspnoea—Temozolomide—malignant glioma	0.000366	0.00686	CcSEcCtD
Salicylate-sodium—Somnolence—Temozolomide—malignant glioma	0.000365	0.00684	CcSEcCtD
Salicylate-sodium—Pain—Carmustine—malignant glioma	0.000363	0.00681	CcSEcCtD
Salicylate-sodium—Constipation—Carmustine—malignant glioma	0.000363	0.00681	CcSEcCtD
Salicylate-sodium—Dyspepsia—Temozolomide—malignant glioma	0.000361	0.00677	CcSEcCtD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—NF1—malignant glioma	0.000359	0.0181	CbGpPWpGaD
Salicylate-sodium—Mesalazine—PTGS2—malignant glioma	0.000357	0.0482	CrCbGaD
Salicylate-sodium—Decreased appetite—Temozolomide—malignant glioma	0.000357	0.00669	CcSEcCtD
Salicylate-sodium—Fatigue—Temozolomide—malignant glioma	0.000354	0.00663	CcSEcCtD
Salicylate-sodium—Constipation—Temozolomide—malignant glioma	0.000351	0.00658	CcSEcCtD
Salicylate-sodium—Pain—Temozolomide—malignant glioma	0.000351	0.00658	CcSEcCtD
Salicylate-sodium—Feeling abnormal—Carmustine—malignant glioma	0.00035	0.00656	CcSEcCtD
Salicylate-sodium—Gastrointestinal pain—Carmustine—malignant glioma	0.000347	0.00651	CcSEcCtD
Salicylate-sodium—PTGS1—Phase 1 - Functionalization of compounds—CYP2B6—malignant glioma	0.000342	0.0172	CbGpPWpGaD
Salicylate-sodium—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—malignant glioma	0.00034	0.0172	CbGpPWpGaD
Salicylate-sodium—Feeling abnormal—Temozolomide—malignant glioma	0.000338	0.00634	CcSEcCtD
Salicylate-sodium—Body temperature increased—Carmustine—malignant glioma	0.000336	0.00629	CcSEcCtD
Salicylate-sodium—Abdominal pain—Carmustine—malignant glioma	0.000336	0.00629	CcSEcCtD
Salicylate-sodium—Gastrointestinal pain—Temozolomide—malignant glioma	0.000336	0.00629	CcSEcCtD
Salicylate-sodium—Urticaria—Temozolomide—malignant glioma	0.000326	0.00611	CcSEcCtD
Salicylate-sodium—Body temperature increased—Temozolomide—malignant glioma	0.000325	0.00608	CcSEcCtD
Salicylate-sodium—Abdominal pain—Temozolomide—malignant glioma	0.000325	0.00608	CcSEcCtD
Salicylate-sodium—PTGS2—S1P1 pathway—PDGFB—malignant glioma	0.000322	0.0163	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—PIM1—malignant glioma	0.00032	0.0161	CbGpPWpGaD
Salicylate-sodium—Hypersensitivity—Carmustine—malignant glioma	0.000313	0.00586	CcSEcCtD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—PIK3CD—malignant glioma	0.000308	0.0156	CbGpPWpGaD
Salicylate-sodium—Acetylsalicylic acid—PTGS2—malignant glioma	0.000307	0.0415	CrCbGaD
Salicylate-sodium—Asthenia—Carmustine—malignant glioma	0.000305	0.00571	CcSEcCtD
Salicylate-sodium—Hypersensitivity—Temozolomide—malignant glioma	0.000302	0.00567	CcSEcCtD
Salicylate-sodium—PTGS2—S1P1 pathway—KDR—malignant glioma	0.000302	0.0153	CbGpPWpGaD
Salicylate-sodium—PTGS1—Phase 1 - Functionalization of compounds—CYP2C18—malignant glioma	0.000296	0.0149	CbGpPWpGaD
Salicylate-sodium—Asthenia—Temozolomide—malignant glioma	0.000295	0.00552	CcSEcCtD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—FN1—malignant glioma	0.000291	0.0147	CbGpPWpGaD
Salicylate-sodium—Diarrhoea—Carmustine—malignant glioma	0.000291	0.00545	CcSEcCtD
Salicylate-sodium—Pruritus—Temozolomide—malignant glioma	0.00029	0.00544	CcSEcCtD
Salicylate-sodium—Dizziness—Carmustine—malignant glioma	0.000281	0.00526	CcSEcCtD
Salicylate-sodium—Diarrhoea—Temozolomide—malignant glioma	0.000281	0.00526	CcSEcCtD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—BCL2—malignant glioma	0.00028	0.0141	CbGpPWpGaD
Salicylate-sodium—Dizziness—Temozolomide—malignant glioma	0.000271	0.00509	CcSEcCtD
Salicylate-sodium—Vomiting—Carmustine—malignant glioma	0.00027	0.00506	CcSEcCtD
Salicylate-sodium—Rash—Carmustine—malignant glioma	0.000268	0.00502	CcSEcCtD
Salicylate-sodium—Dermatitis—Carmustine—malignant glioma	0.000268	0.00501	CcSEcCtD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—PTGS2—malignant glioma	0.000266	0.0134	CbGpPWpGaD
Salicylate-sodium—Headache—Carmustine—malignant glioma	0.000266	0.00499	CcSEcCtD
Salicylate-sodium—Vomiting—Temozolomide—malignant glioma	0.000261	0.00489	CcSEcCtD
Salicylate-sodium—Rash—Temozolomide—malignant glioma	0.000259	0.00485	CcSEcCtD
Salicylate-sodium—Dermatitis—Temozolomide—malignant glioma	0.000259	0.00485	CcSEcCtD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—CXCL8—malignant glioma	0.000258	0.013	CbGpPWpGaD
Salicylate-sodium—Headache—Temozolomide—malignant glioma	0.000257	0.00482	CcSEcCtD
Salicylate-sodium—PTGS2—Spinal Cord Injury—BCAN—malignant glioma	0.000257	0.013	CbGpPWpGaD
Salicylate-sodium—PTGS2—Arachidonic acid metabolism—PTGS1—malignant glioma	0.000254	0.0128	CbGpPWpGaD
Salicylate-sodium—Salicylic acid—PTGS2—malignant glioma	0.000253	0.0342	CrCbGaD
Salicylate-sodium—Nausea—Carmustine—malignant glioma	0.000252	0.00473	CcSEcCtD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—PIK3CD—malignant glioma	0.000245	0.0124	CbGpPWpGaD
Salicylate-sodium—Nausea—Temozolomide—malignant glioma	0.000244	0.00457	CcSEcCtD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—BCL2—malignant glioma	0.000222	0.0112	CbGpPWpGaD
Salicylate-sodium—PTGS1—Eicosanoid Synthesis—PTGS2—malignant glioma	0.000221	0.0111	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—MYB—malignant glioma	0.000213	0.0108	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—GDNF—malignant glioma	0.000207	0.0105	CbGpPWpGaD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—CXCL8—malignant glioma	0.000205	0.0103	CbGpPWpGaD
Salicylate-sodium—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—malignant glioma	0.000191	0.00964	CbGpPWpGaD
Salicylate-sodium—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—malignant glioma	0.000185	0.00932	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—CYP2B6—malignant glioma	0.000181	0.00916	CbGpPWpGaD
Salicylate-sodium—PTGS1—Overview of nanoparticle effects—TNF—malignant glioma	0.00018	0.00907	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—GFAP—malignant glioma	0.000178	0.00899	CbGpPWpGaD
Salicylate-sodium—PTGS2—S1P1 pathway—VEGFA—malignant glioma	0.000166	0.0084	CbGpPWpGaD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—PTGS1—malignant glioma	0.000162	0.00817	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—CYP2C18—malignant glioma	0.000157	0.00794	CbGpPWpGaD
Salicylate-sodium—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—malignant glioma	0.000157	0.00793	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—LGALS3—malignant glioma	0.000156	0.00786	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—SOD1—malignant glioma	0.000154	0.0078	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—STMN1—malignant glioma	0.000149	0.0075	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—CAT—malignant glioma	0.000147	0.0074	CbGpPWpGaD
Salicylate-sodium—PTGS2—Overview of nanoparticle effects—TNF—malignant glioma	0.000143	0.0072	CbGpPWpGaD
Salicylate-sodium—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—malignant glioma	0.00014	0.00705	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—GSTT1—malignant glioma	0.000127	0.00642	CbGpPWpGaD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—malignant glioma	0.000124	0.00625	CbGpPWpGaD
Salicylate-sodium—PTGS1—Arachidonic acid metabolism—PTGS2—malignant glioma	0.000123	0.0062	CbGpPWpGaD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—SOD1—malignant glioma	0.000123	0.00619	CbGpPWpGaD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—CAT—malignant glioma	0.000116	0.00588	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—HES1—malignant glioma	0.000115	0.00579	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—NCOR1—malignant glioma	0.000114	0.00576	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—PLK1—malignant glioma	0.000113	0.00568	CbGpPWpGaD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—RAF1—malignant glioma	0.000108	0.00544	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—F2—malignant glioma	0.000107	0.00543	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—malignant glioma	0.000107	0.00539	CbGpPWpGaD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—malignant glioma	0.000102	0.00513	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—GJA1—malignant glioma	0.0001	0.00506	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—PML—malignant glioma	9.52e-05	0.0048	CbGpPWpGaD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—malignant glioma	9.45e-05	0.00477	CbGpPWpGaD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—malignant glioma	9.05e-05	0.00457	CbGpPWpGaD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—malignant glioma	9.03e-05	0.00456	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—RTEL1—malignant glioma	8.92e-05	0.0045	CbGpPWpGaD
Salicylate-sodium—PTGS1—Biological oxidations—GSTP1—malignant glioma	8.82e-05	0.00445	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—TOP2A—malignant glioma	8.7e-05	0.00439	CbGpPWpGaD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—F2—malignant glioma	8.53e-05	0.00431	CbGpPWpGaD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—malignant glioma	8.21e-05	0.00414	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—IFNG—malignant glioma	8.15e-05	0.00411	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—PTGS2—malignant glioma	7.81e-05	0.00394	CbGpPWpGaD
Salicylate-sodium—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—malignant glioma	7.72e-05	0.00389	CbGpPWpGaD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—MYC—malignant glioma	7.55e-05	0.00381	CbGpPWpGaD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—EGFR—malignant glioma	7.39e-05	0.00373	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—IL1B—malignant glioma	7.27e-05	0.00367	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—RTEL1—malignant glioma	7.08e-05	0.00357	CbGpPWpGaD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—TNF—malignant glioma	7.03e-05	0.00355	CbGpPWpGaD
Salicylate-sodium—PTGS2—Aryl Hydrocarbon Receptor—KRAS—malignant glioma	6.98e-05	0.00352	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—CDKN2A—malignant glioma	6.88e-05	0.00347	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—BCL2—malignant glioma	6.77e-05	0.00342	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—NTRK1—malignant glioma	6.77e-05	0.00342	CbGpPWpGaD
Salicylate-sodium—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—malignant glioma	6.58e-05	0.00332	CbGpPWpGaD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—IFNG—malignant glioma	6.47e-05	0.00326	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—IDH1—malignant glioma	6.37e-05	0.00322	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—malignant glioma	6.29e-05	0.00318	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—malignant glioma	6.24e-05	0.00315	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	6.17e-05	0.00311	CbGpPWpGaD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—IL1B—malignant glioma	5.77e-05	0.00291	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—PDGFRA—malignant glioma	5.67e-05	0.00286	CbGpPWpGaD
Salicylate-sodium—PTGS1—Selenium Micronutrient Network—TNF—malignant glioma	5.27e-05	0.00266	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—COX8A—malignant glioma	5.12e-05	0.00259	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—IFNG—malignant glioma	5.11e-05	0.00258	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—FGFR1—malignant glioma	5.06e-05	0.00256	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—IDH1—malignant glioma	5.06e-05	0.00255	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	4.9e-05	0.00247	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—CXCL8—malignant glioma	4.76e-05	0.0024	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—MYC—malignant glioma	4.66e-05	0.00235	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—IL1B—malignant glioma	4.56e-05	0.0023	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—CASP3—malignant glioma	4.55e-05	0.0023	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—IL2—malignant glioma	4.54e-05	0.00229	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—BAD—malignant glioma	4.54e-05	0.00229	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—APC—malignant glioma	4.39e-05	0.00222	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—ASMT—malignant glioma	4.36e-05	0.0022	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—EGF—malignant glioma	4.34e-05	0.00219	CbGpPWpGaD
Salicylate-sodium—PTGS2—C-MYB transcription factor network—KRAS—malignant glioma	4.31e-05	0.00218	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—MMP9—malignant glioma	4.3e-05	0.00217	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	4.26e-05	0.00215	CbGpPWpGaD
Salicylate-sodium—PTGS2—Selenium Micronutrient Network—TNF—malignant glioma	4.19e-05	0.00211	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—BCAN—malignant glioma	4.09e-05	0.00207	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—COX8A—malignant glioma	4.07e-05	0.00205	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—BCAN—malignant glioma	3.88e-05	0.00196	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—FGF2—malignant glioma	3.7e-05	0.00187	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—malignant glioma	3.63e-05	0.00183	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—MYC—malignant glioma	3.55e-05	0.00179	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—malignant glioma	3.51e-05	0.00177	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—DTX1—malignant glioma	3.51e-05	0.00177	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—EGFR—malignant glioma	3.48e-05	0.00175	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—malignant glioma	3.46e-05	0.00175	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—ASMT—malignant glioma	3.46e-05	0.00174	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—malignant glioma	3.45e-05	0.00174	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—malignant glioma	3.41e-05	0.00172	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	3.38e-05	0.00171	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—TNF—malignant glioma	3.31e-05	0.00167	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—IDH2—malignant glioma	3.3e-05	0.00167	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—BCAN—malignant glioma	3.25e-05	0.00164	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	3.11e-05	0.00157	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CYP2B6—malignant glioma	3.1e-05	0.00157	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—malignant glioma	3.1e-05	0.00156	CbGpPWpGaD
Salicylate-sodium—PTGS2—Spinal Cord Injury—TP53—malignant glioma	2.92e-05	0.00147	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—malignant glioma	2.91e-05	0.00147	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—IDH1—malignant glioma	2.84e-05	0.00143	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—HEY2—malignant glioma	2.75e-05	0.00139	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—SPHK1—malignant glioma	2.75e-05	0.00139	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CYP2C18—malignant glioma	2.69e-05	0.00136	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—IDH1—malignant glioma	2.69e-05	0.00136	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—malignant glioma	2.63e-05	0.00133	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—IDH2—malignant glioma	2.62e-05	0.00132	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—HEY1—malignant glioma	2.55e-05	0.00129	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	2.54e-05	0.00128	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—HIST1H3B—malignant glioma	2.48e-05	0.00125	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	2.47e-05	0.00125	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CYP2B6—malignant glioma	2.46e-05	0.00124	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	2.42e-05	0.00122	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	2.36e-05	0.00119	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	2.31e-05	0.00117	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—JAG2—malignant glioma	2.26e-05	0.00114	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—IDH1—malignant glioma	2.25e-05	0.00114	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	2.25e-05	0.00114	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	2.23e-05	0.00113	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	2.23e-05	0.00113	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—SPHK1—malignant glioma	2.18e-05	0.0011	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GSTT1—malignant glioma	2.18e-05	0.0011	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CYP2C18—malignant glioma	2.14e-05	0.00108	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	2.05e-05	0.00104	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	2.03e-05	0.00103	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	2.01e-05	0.00102	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	1.99e-05	0.001	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—H3F3A—malignant glioma	1.91e-05	0.000966	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—BCHE—malignant glioma	1.9e-05	0.000957	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—SLC5A5—malignant glioma	1.87e-05	0.000945	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.83e-05	0.000926	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—JAG1—malignant glioma	1.8e-05	0.000911	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1.77e-05	0.000894	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.77e-05	0.000894	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—FBXW7—malignant glioma	1.77e-05	0.000892	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	1.75e-05	0.000886	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GSTT1—malignant glioma	1.73e-05	0.000872	CbGpPWpGaD
Salicylate-sodium—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	1.68e-05	0.000846	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PTGS1—malignant glioma	1.62e-05	0.000817	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.61e-05	0.000814	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1.53e-05	0.000772	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—GSTP1—malignant glioma	1.51e-05	0.000761	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—BCHE—malignant glioma	1.5e-05	0.00076	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—SLC5A5—malignant glioma	1.49e-05	0.00075	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CAT—malignant glioma	1.47e-05	0.000741	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1.41e-05	0.00071	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—NCOR1—malignant glioma	1.39e-05	0.0007	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—CDKN2B—malignant glioma	1.39e-05	0.000699	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—HES1—malignant glioma	1.32e-05	0.000667	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—NCOR1—malignant glioma	1.31e-05	0.000663	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PDGFRA—malignant glioma	1.26e-05	0.000635	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1.21e-05	0.000613	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—GSTP1—malignant glioma	1.2e-05	0.000604	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CAT—malignant glioma	1.17e-05	0.000588	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—TERT—malignant glioma	1.16e-05	0.000584	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—HLA-A—malignant glioma	1.16e-05	0.000584	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PDGFB—malignant glioma	1.13e-05	0.00057	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—CAV1—malignant glioma	1.13e-05	0.00057	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—FGFR1—malignant glioma	1.12e-05	0.000567	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—HIF1A—malignant glioma	1.11e-05	0.000559	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—NCOR1—malignant glioma	1.1e-05	0.000555	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.08e-05	0.000545	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—CAV1—malignant glioma	1.07e-05	0.000541	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PIK3CG—malignant glioma	1.03e-05	0.000519	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—BAD—malignant glioma	1.01e-05	0.000508	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—NOTCH1—malignant glioma	9.98e-06	0.000504	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PPARG—malignant glioma	9.93e-06	0.000501	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—CD80—malignant glioma	9.77e-06	0.000493	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—APC—malignant glioma	9.76e-06	0.000492	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—EGF—malignant glioma	9.64e-06	0.000487	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PTPN11—malignant glioma	9.58e-06	0.000484	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—BRAF—malignant glioma	9.17e-06	0.000463	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PIK3CD—malignant glioma	9.05e-06	0.000457	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—CAV1—malignant glioma	8.97e-06	0.000453	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—AKT2—malignant glioma	8.93e-06	0.000451	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PIK3CD—malignant glioma	8.58e-06	0.000433	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	8.57e-06	0.000433	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—FGF2—malignant glioma	8.21e-06	0.000414	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PIK3CG—malignant glioma	8.17e-06	0.000412	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PIK3CB—malignant glioma	7.89e-06	0.000398	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PPARG—malignant glioma	7.89e-06	0.000398	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PTGS2—malignant glioma	7.81e-06	0.000394	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—MDM2—malignant glioma	7.68e-06	0.000388	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—RAF1—malignant glioma	7.66e-06	0.000386	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—ERBB2—malignant glioma	7.58e-06	0.000382	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PIK3CB—malignant glioma	7.48e-06	0.000377	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PIK3CD—malignant glioma	7.18e-06	0.000363	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PTEN—malignant glioma	6.81e-06	0.000344	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PTEN—malignant glioma	6.46e-06	0.000326	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PIK3CB—malignant glioma	6.26e-06	0.000316	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—STAT3—malignant glioma	5.78e-06	0.000292	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PTEN—malignant glioma	5.41e-06	0.000273	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—MYC—malignant glioma	5.37e-06	0.000271	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—EGFR—malignant glioma	5.25e-06	0.000265	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—KRAS—malignant glioma	4.96e-06	0.00025	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—PIK3CA—malignant glioma	4.81e-06	0.000243	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—PIK3CA—malignant glioma	4.56e-06	0.00023	CbGpPWpGaD
Salicylate-sodium—PTGS1—Metabolism—AKT1—malignant glioma	3.93e-06	0.000198	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—PIK3CA—malignant glioma	3.82e-06	0.000193	CbGpPWpGaD
Salicylate-sodium—PTGS2—Disease—AKT1—malignant glioma	3.72e-06	0.000188	CbGpPWpGaD
Salicylate-sodium—PTGS2—Metabolism—AKT1—malignant glioma	3.12e-06	0.000157	CbGpPWpGaD
